@isaacbstoner@OctagonTx Great News Issac! We at Rubik share your commitment to adding diverse perspectives to the team. BTW, could you provide a warm intro to John Cena? We want to build a similar advisory, but more stripped down.
We had a great time at #AACR23 this past week. It was a pleasure to have attendees meet our team and engage in open discussions to gain further insight into our posters highlighting Actinium’s work towards targeted radiotherapy R&D. More here: https://t.co/kdvkIt9yh7 $ATNM
🌟Long-awaited proof-of-concept that CAR-T can eradicate solid tumours - and in immune cold paediatric tumours. Brava, Locatelli and Precision Medicine Team at Ospedale Pediatrico Bambino Gesù!
https://t.co/wMQWXiYe33
Actinium is focused on the development of targeted radiotherapies. Learn more about new data from our HER3 targeting radiotherapy program as well as our novel strategy utilizing Actimab-A to deplete MDSCs by visiting our abstracts ahead of #AACR23: https://t.co/xg27ybHjSq $ATNM
This is so awesome! Thanks so much for sharing and the awesome description in the Git🥳
It seems like we are more and more shifting from 'how to design' to 'what to design' 💪
The new PSG score is a PSMA-PET Whole-Body Tumor-to-Salivary Gland Ratio to estimate the target expression at the whole body level using the PET MIP to Predict Response to 177Lu-PSMA (PLUVICTO). Tested by 10 international experts on 237 patients. https://t.co/pfr95zMar7
Today we're making RF Diffusion, our guided diffusion model for protein design with potential applications in medicine, vaccines & advanced materials, free to use. The software has proven much faster and more capable than prior protein design tools.
https://t.co/lhkhBZNzYc
STEAP2: 2nd priority hit from Owen Witte's '18 surfaceome discovery paper. Broad expression in normal tissue, including lung. Uniformly high in prostate cancer.
Finally, here is the link to the paper @NatureComms
https://t.co/uy9IrMyB2o
The data compiled here is a valuable resource for #cancer#genomics analyses.
It can also be quite easily further mined & visualized *interactively* via this nice portal:
https://t.co/POKBbmCvtL
Amazing and inspiring story and first clear evidence of the power of combining gene therapy with cell/immune therapy. It took a lot of courage for both Emily and her family and her doctors @BLLPHD@carlhjune@GruppSteve
More + data for solid tumor cell tx @immatics IMA203 anti-PRAME TCR-T: 19-50% cORR (↑dose ↑ORR). 13/32 are melanoma pts, curious about ORR after checkpoint Rx, expect common mechanisms of resistance